Whole-leg Ultrasound in Pregnant Patients (CLOT-3)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01319474|
Recruitment Status : Recruiting
First Posted : March 21, 2011
Last Update Posted : August 7, 2019
|Condition or disease||Intervention/treatment||Phase|
|Deep Vein Thrombosis||Other: Whole-leg compression ultrasound||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||268 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Use of Whole-leg Ultrasound for Diagnosis of Deep Vein Thrombosis in Pregnant Patients|
|Study Start Date :||February 2011|
|Estimated Primary Completion Date :||July 31, 2020|
|Estimated Study Completion Date :||December 31, 2020|
Ultrasound for suspected DVT
Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
Other: Whole-leg compression ultrasound
Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
- Symptomatic VTE [ Time Frame: Three months ]The primary outcome measure will be DVT or PE, or death attributable to thromboembolic disease confirmed by objective testing in the 3 months following enrollment.
- Isolated iliac DVT [ Time Frame: At enrollment ]The exact rate of isolated iliac vein DVT identified on futher testing performed on the basis of suspicious doppler ultrasound findings.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01319474
|Contact: Valerie Aston, MBA, RT||(801) firstname.lastname@example.org|
|Contact: Scott Stevens, MD||(801) 507- 3747||Scott.Stevens@imail.org|
|United States, Utah|
|Intermoutain Medical Center||Recruiting|
|Murray, Utah, United States, 84157|
|Contact: Scott M Stevens, MD 801-507-3310 email@example.com|
|Principal Investigator: Scott M Stevens, MD|
|Principal Investigator:||Scott M Stevens, MD||Intermountain Health Care, Inc.|